+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease

American Journal of Cardiology 104(6): 798-804

Lowering of low-density lipoprotein (LDL) cholesterol is a fundamental step in the comprehensive management of patients at high risk for cardiovascular events. The combination of a statin with ezetimibe usually provides additional LDL cholesterol lowering compared to statin monotherapy. This open-label observational study evaluated the impact of a 26-week treatment program with uptitration of statin dosages and incorporation of ezetimibe 10 mg therapy in 2,577 men and women (median age 64 years) with hypercholesterolemia and an LDL cholesterol level >2.5 mmol/L (97 mg/dl). Attainment of an LDL cholesterol target of 2.5 mmol/L (97 mg/dl) increased with consecutive visits (63%, 67%, and 71% at the second, third, and final visits, respectively). Current guideline-recommended LDL cholesterol value <2.0 mmol/L (77 mg/dl) was achieved by 36%, 40%, and 41% of the group at the same consecutive follow-up sessions. Median LDL cholesterol decreased from 3.0 mmol/L (116 mg/dl) at baseline to 2.1 mmol/L (81 mg/dl) at the end of the 26-week monitoring period. Favorable changes were concomitantly observed for median total cholesterol (5.1 to 4.1 mmol/L [197 to 159 mg/dl]), total cholesterol/high-density lipoprotein cholesterol ratio (4.2 to 3.3), and triglyceride (1.6 to 1.4 mmol/L [142 to 124 mg/dl]). Of those who attended visit 4, 48% exhibited LDL cholesterol lowering of > or =1 mmol/L (39 mg/dl) compared to baseline levels. In conclusion, an algorithm-based statin uptitration/ezetimibe combination regimen is useful to increase LDL cholesterol lowering where statin monotherapy has not achieved target lipid values.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056809266

Download citation: RISBibTeXText

PMID: 19733714

DOI: 10.1016/j.amjcard.2009.05.019

Related references

Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. American Journal of Cardiology 116(12): 1798-1801, 2015

Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology 27(2): 138-145, 2011

Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: clinical impact of combination therapy with ezetimibe. Current Therapeutic Research Clinical and Experimental 73(1-2): 1-15, 2012

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Journal of Clinical Lipidology 8(1): 107-116, 2014

Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. American Journal of Cardiology 123(2): 233-238, 2019

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. American Journal of Cardiology 101(4): 483-485, 2008

The Effect of Ezetimibe/Statin Combination and High-Dose Statin Therapy on Thyroid Autoimmunity in Women with Hashimoto's Thyroiditis and Cardiovascular Disease: A Pilot Study. Experimental and Clinical Endocrinology and Diabetes 124(9): 577-581, 2016

Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. Journal of Cardiovascular Pharmacology and Therapeutics 13(1): 72-79, 2008

Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?. Preventive Cardiology 10(1): 31-35, 2007

Ezetimibe in combination with a statin does not reduce all-cause mortality. Journal of Clinical Medicine Research 5(4): 275-280, 2013

High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis 227(1): 118-124, 2013

Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe. Immunology Endocrine & Metabolic Agents - Medicinal Chemistry 8(2): 177-182, 2008

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids in Health and Disease 8: 41, 2009

Ezetimibe-Statin Combination to Reduce Cardiovascular Events: The Evidence Base. Metabolic Syndrome and Related Disorders 13(8): 327-328, 2015

Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease. Journal of Cardiovascular Nursing 27(4): 303-316, 2012